Zhixian Zhang , Qianhui Shen , Yanping Chen , Zhi Liang , Yuan Liu , Yu Ren , Cailv Wei , Kang Jia , Chao Ding , Shisong Wang , Rongbiao Pi
{"title":"Design and characterization of N-oxide cinnamanilide derivative PX5–9: Improved solubility and BDNF upregulation","authors":"Zhixian Zhang , Qianhui Shen , Yanping Chen , Zhi Liang , Yuan Liu , Yu Ren , Cailv Wei , Kang Jia , Chao Ding , Shisong Wang , Rongbiao Pi","doi":"10.1016/j.bmcl.2025.130266","DOIUrl":null,"url":null,"abstract":"<div><div>Compound <strong>5</strong>, a cinnamanilide derivative, upregulates brain derivated neurotrophic factor (BDNF) expression but with low soluablity. In this study, <strong>PX5–9</strong>, a N-oxide derivative of <strong>5</strong>, demonstrated significant protective effects in the HT22 glutamate-induced toxicity model and showed no significant toxicity at 30 μM. Western blot analysis confirmed that <strong>PX5–9</strong> increased BDNF levels similar to <strong>5</strong>. Solubility tests revealed a significant improvement in <strong>PX5–9</strong> (37.10 ± 0.33 μg/mL) compared to <strong>5</strong> (< 15 ng/mL). Pharmacokinetic studies of <strong>PX5–9</strong> revealed favorable properties, fast absorption and also can be transformated into parent compound <strong>5</strong>, suggesting it is a potential candidate for these diseases involving with BDNF. The N-oxide modification might be a good prodrug design to enhance solubility while preserving biological activity.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"125 ","pages":"Article 130266"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X25001751","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Compound 5, a cinnamanilide derivative, upregulates brain derivated neurotrophic factor (BDNF) expression but with low soluablity. In this study, PX5–9, a N-oxide derivative of 5, demonstrated significant protective effects in the HT22 glutamate-induced toxicity model and showed no significant toxicity at 30 μM. Western blot analysis confirmed that PX5–9 increased BDNF levels similar to 5. Solubility tests revealed a significant improvement in PX5–9 (37.10 ± 0.33 μg/mL) compared to 5 (< 15 ng/mL). Pharmacokinetic studies of PX5–9 revealed favorable properties, fast absorption and also can be transformated into parent compound 5, suggesting it is a potential candidate for these diseases involving with BDNF. The N-oxide modification might be a good prodrug design to enhance solubility while preserving biological activity.
期刊介绍:
Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.